Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/42"

PredicateValue (sorted: default)
rdfs:label
rdf:type
?:Evidence_enzyme_system
?:Evidence_numb_subjects
?:Evidence_object_dose
?:Evidence_precip_dose
?:Evidence_type
?:Evidence_value
?:content
"Route of administration: oral study duration: 40mg of simvastatin to establish baseline given two seperate times with a one day gap; after a >1 week washout period participants were given 10 days treatment ketoconazole 40mg 1x/day. 40mg of simvastatin was given during this phase once on day 6 and once on day nine. population: 19 (20 - 1 dropout) 9 male, 10 women ages:30-47 AUC_i/AUC (0 to infinity):12.55 description: This study used an open-label, fixed-sequential, 3-way crossover study design. Nineteen subjects received oral doses of 0.075 mg/kg midazolam and 40 mg simvastatin during 3 phases (baseline, after inhibition with 400 mg ketoconazole for 10 days, and after induction with 600 mg rifampin [INN, rifampicin] for 9 days). Serial plasma concentrations of midazolam and simvastatin were obtained. Oral clearances of midazolam and simvastatin were compared. RESULTS: Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001)"
dc:creator
dc:date
"10/30/2007 11:25:31"
rdfs:seeAlso

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ ketoconazole_increases_auc_simvastatin, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1424 }

Context graph